Please assess the completion status of the following clinical trial:

Trial Title: Fluphenazine Decanoate for Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults 18 to 65 years of age with psoriasis, in general good health~* Must have symmetric target lesions approximately 2-4 cm in diameter on each side of the body (e.g., thighs) with baseline target lesion score of 6 or higher (scale of 0-12) for each target~* Women of childbearing potential must agree to use two forms of contraception for the duration of the study~Exclusion Criteria:~* Infliximab (Remicade) or alefacept (Amevive) within the past 6 months (24 weeks)~* Etanercept (Enbrel), efalizumab (Raptiva), adalimumab (Humira), or other tumor necrosis factor- (TNF)-alpha inhibitor within the past 3 months (12 weeks)~* Other systemic psoriasis therapies (e.g., methotrexate, cyclosporine, acitretin) or PUVA (psoralen plus ultraviolet A) within the past 4 weeks~* Ultraviolet B (UVB) or topical therapy (other than over the counter (OTC) moisturizers and shampoos) within the past 2 weeks (including topical corticosteroids, vitamin A and D analogues)~* Receipt of an investigational agent within the past 4 weeks~* Systemic corticosteroid therapy~* Inability to understand consent or comply with protocol~* Pregnancy, lactation, or unwillingness to use adequate birth control during the study~* Impaired hepatic function~* Known Human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS), hepatitis B/C~* Blood dyscrasia~* Epilepsy~* Tardive dyskinesia~* Excessive alcohol consumption~* Current use of selective serotonin reuptake inhibitors (SSRI), tricyclic, or norephinephrine reuptake inhibitor antidepressants or use within 6 weeks of beginning the study~* Concurrent use of anti-seizure drugs, with the exception of gabapentin for treatment of neuropathy~* Use of phenothiazine antipsychotics or anticholinergics~* Known allergy to fluphenazine decanoate or other phenothiazines~* Known allergy to parabens/para-aminobenzoic acid (PABA), benzyl alcohol, sesame oil or sesame seeds~* Clinically significant mitral valve disease~* Clinically significant and uncontrolled cardiovascular disease~* QTc \>450 msec, or evidence of a clinically significant dysrhythmia on electrocardiography (ECG)~* Operator of heavy machinery~* Pheochromocytoma~* History of breast cancer~* History of seizure disorder~* Occupational exposure to organophosphate insecticides~* Parkinson's disease and other related movement disorders~* Lab abnormalities including:~* Alanine aminotranferease (ALT)/aspartate aminotransferase (AST) ≥ 2X upper limit of reference range~* Creatinine ≥ 1.5X upper limit of reference range~* Bilirubin ≥ 2X upper limit of reference range~* Absolute total lymphocyte or polymorphonuclear leucocyte count ≤ 1000/uL or ≥ 3X upper limit of ref range~* Platelets ≤ 80,000/uL~* Hemoglobin ≤ 8.0 g/dL~* Glucose ≥ 200 mg/dL~* Fasting blood sugar ≥ 126 mg/dL~* Concurrent use of drugs listed in Appendix F

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Fluphenazine treated (Type: EXPERIMENTAL): Treated with fluphenazine
- Placebo (Type: PLACEBO_COMPARATOR): Treated with Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues